Division of Radiation Oncology Biomarker Initiative (Research Protocol: PA18-0644)
This is a discovery and exploratory protocol that enables us to obtain serial biospecimen from patients, across tumor type, who will be evaluated for radiation treatment at MD Anderson. The biospecimen includes blood, tissue, CSF (cerebrospinal fluid), saliva, buccal swab, skin swab; stool, abdominal or pleural fluid.
How we are doing (Patient accrual by RO section or by study)
As of December 31, 2022, 218 patients have been enrolled on the Biomarker Initiative IRB-approved Laboratory Study (PA18-0644). Patient breakdown is as follows:
- 32% from the Section of Melanoma/Sarcoma Radiation Oncology
- 18% from the Section of Hematologic Radiation Oncology
- 22% from the Section of Central Nervous System (CNS) Radiation Oncology
- 6% from the Department of Gastrointestinal (GI) Radiation Oncology
- 7% from the Section of Head and Neck (H&N) Radiation Oncology
- 11% from the Department of Breast Radiation Oncology
From our inception in 2019 through December 31, 2022, we have supported 22 clinical trials and cohorts of interest with correlative research biospecimen collections in the Division of Radiation Oncology. The cumulative accrual graphic above shows the breakdown of accrual by study, including 20 of the trials for which patients co-consented to PA18-0644.
If you are opening a clinical trial, writing a grant with biospecimen collection, have an ongoing trial and need biospecimen help, or just want to learn more about biospecimen collection/processing, please contact us at ROBiomarkerInitiative
The Radiation Oncology Strategic Biomarker Initiative is generously funded in part by the J. Donald Childress Foundation. All publications that have relied upon biospecimen collecting, processing, or data generated by the Radiation Oncology Biomarker Initiative, should acknowledge that their study was supported in part by the J. Donald Childress Foundation and the Radiation Oncology Strategic Biomarker Initiative.
Please send the citation of the publication to our email: ROBiomarkerInitiative
Who we are supporting (Principal Investigator listed per disease site)
Head & Neck: